1. At a Glance – The Fever Is Back, But The Patient Is Sweating
Valiant Laboratories is trading at ₹61.2 with a market cap of ₹333 crore. In the last 3 months, the stock is down 23%. Six months? Down 31.9%. One year? Down 30.6%. If charts could cry, this one would need paracetamol.
Latest quarterly sales stand at ₹52.46 crore, up 48.9% YoY. Sounds heroic? Wait for it. PAT came in at ₹-7.06 crore. Yes, negative. EPS for the quarter: ₹-1.30.
ROE? -1.43%.
ROCE? -0.95%.
Debt? ₹53.8 crore.
OPM? 2.66%.
EV/EBITDA? 69.9.
The company manufactures paracetamol API. Irony check: the company that makes fever medicine is running a temperature itself.
And here’s the twist — they just concluded audited quarterly results for December 2025. So yes, this is officially Quarterly Results (Q3 FY26). Locking it. EPS annualisation rules apply accordingly.
So the question is simple: Is this a temporary fever or chronic weakness?
Let’s investigate like a forensic auditor who also watches crime thrillers.
2. Introduction – From IPO Dreams to GST Notices
Valiant Laboratories was incorporated in 1980. That’s older than most startup founders who pitch “disruption.”
The company manufactures Paracetamol API — the active ingredient used to treat headache, fever, arthritis, muscle aches, toothache, cold. Basically, everything except investor heartbreak.
They went public in October 2023. IPO size? ₹152.46 crore. 1.089 crore shares. Freshly listed. Freshly funded.
Then reality happened.
Revenue in FY23 was ₹334 crore. In FY24 it dropped to ₹182 crore. FY25? ₹133 crore. TTM? ₹203 crore.
Profit? From ₹29 crore in FY23 to ₹0 in FY24 to ₹-2 crore in FY25 to ₹-4 crore TTM.
Meanwhile, credit rating agencies downgraded them to BBB/Negative. GST authorities sent notices. Rights issue announced. More funds raised.
This is not a smooth Bollywood success story. This is a web series with plot twists.
But before judging, let’s understand what they actually do.
3. Business Model – WTF Do They Even Do?
Valiant is in the Active Pharmaceutical Ingredient (API) business.
Their main product? Paracetamol API.
Available in:
- Powder
- Fine Powder
- Crystals
Installed capacity: 9,000 MTPA
Plant location: Palghar, Maharashtra
Certified: GMP and ISO 9001:2015
Revenue breakup FY24:
- 94% from manufactured products
- 1%
